--(SEQ ID NO: 5)--.

In claim 45, after "C is Trp, D-Pal, D-Nal", please delete "L-Nal-D-Pal(N-O)" and insert -L-Nal, D-Pal(N-O)--.

In claim 47, after "Lys(iPr)-Pro-" and before "Ala", please insert --D---.

In claim 71, after "A-B-C-D-E-F-G-H-I-J", please insert --(SEQ ID NO: 6)--.

In claim 71, after "C is Trp, D-Pal, D-Nal", please delete "L-Nal-D-Pal(N-O)" and insert --L-Nal, D-Pal(N-O)--.

REMARKS

The substitute Sequence Listing that has been amended to comply with 37 C.F.R. §1.821-1.825. Pursuant to 37 C.F.R. §1.821(a)(2), and the Examiner's comments that "[p]eptides consisting *entirely* of four or more L-amino acids . . . are subject to the rules" (emphasis added), Applicant has not included in the Sequence Listing specific compounds disclosed in the specification that comprise at least one D-amino acid. Moreover, for the generic compounds disclosed in the specification in which certain amino acid positions may be occupied by either an L- or a D-amino acid, only the L-amino acid(s) that may occupy a particular position within the generic structure has been included in the Sequence Listing. Applicant's representative has consulted by telephone with Examiner Robert Wax regarding compliance with the Sequence Listing requirements and believes that the enclosed substitute Sequence Listing is in full compliance with the rules.

Applicant is submitting concurrently herewith a computer readable form of the Sequence Listing (diskette) which is identical in substance to the paper copy of the

Group Art Unit: 1811

Sequence Listing submitted herewith. No new matter has been added to either the paper or computer readable copies of the substitute Sequence Listing.

The specification and claims have been amended to identify sequences therein with the appropriate SEQ ID NO: identifier. Additionally, the specification and claims have been amended to correct certain informalities. In particular, the term "L-Nal-D-Pal(N-O)" throughout the specification and claims was incorrect due to a typographical error and has been corrected to read "L-Nal, D-Nal(P-O)". Additionally, several chemical formulas throughout the specification and claims recited "Asp" instead of "D-Asp" at position 10 of the peptidomimetic compound, due to a typographical error. A "D" has been added to these formulas to correct this typographical error. Support for "D-Asp" at position 10 of the peptidomimetic compounds can be found in the compounds listed in Table 1 (at pages 24-30 of the specification). No new matter has been added by way of the amendments to the specification and claims. Applicant respectfully requests that these amendments be entered.

SUMMARY

Applicant submits that the claims are in condition for allowance. If a telephone conversation with Applicant's Agent would expedite the prosecution of the above-identified application, the examiner is urged to call Applicant's Agent at (617) 227-7400.

Respectfully submitted,

Catherine J. Kara

Registration No. P41,106

Agent for Applicants

LAHIVE & COCKFIELD, LLP 60 State Street Boston, MA 02109 Tel. (617) 227-7400

Dated: July 2, 1997